Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Medico Remedies Limited is an Indian specialty and generic pharmaceutical manufacturer operating in domestic and export markets. The company produces formulations across therapeutic segments with a focus on chronic disease treatments, competing in India's fragmented pharma landscape where pricing pressure from government regulation and generic competition is offset by volume growth from expanding healthcare access. Stock performance is driven by new product approvals, API cost management, and export market penetration particularly to regulated markets.
Medico generates revenue by manufacturing and selling generic pharmaceutical formulations with pricing determined by competitive intensity and regulatory frameworks. In India, National Pharmaceutical Pricing Authority (NPPA) controls prices for essential medicines, limiting pricing power but ensuring volume stability. Gross margins of 28.2% reflect competitive generic pricing and API input costs, while the 24.1% operating margin indicates efficient manufacturing scale and controlled SG&A. The company benefits from India's cost-competitive manufacturing base for export arbitrage, though faces margin pressure from API price volatility (often USD-denominated imports) and regulatory compliance costs for US FDA and EU approvals. Limited R&D spending focuses on bioequivalence studies for generic filings rather than novel drug development.
New product launch pipeline and ANDA/DMF approvals for US and regulated markets, which drive revenue growth expectations
API and raw material cost trends, particularly for key inputs sourced from China, affecting gross margin sustainability
Domestic volume growth driven by chronic disease prevalence (diabetes, cardiovascular) and healthcare penetration in tier-2/3 cities
Export revenue momentum and market share gains in key geographies, with US generics being particularly margin-accretive
Regulatory inspection outcomes (US FDA, MHRA) and warning letters that can halt exports from specific facilities
Intensifying price erosion in US generics market due to channel consolidation and increased competition, with average selling prices declining 5-10% annually for mature products
Regulatory compliance burden increasing with stricter US FDA and global inspections, requiring continuous capex investment (estimated 3-5% of sales) to maintain certifications and remediate observations
API supply chain concentration in China and geopolitical risks affecting raw material availability and costs, with limited backward integration
Fragmented Indian pharma market with over 3,000 manufacturers creating intense pricing competition, particularly in acute segments where brand loyalty is low
Large generic players (Sun Pharma, Dr. Reddy's, Cipla) with superior scale, R&D capabilities, and established US distribution networks can outbid for product acquisitions and launch at-risk
Biosimilar and complex generic competition from well-capitalized players may limit growth in higher-margin specialty segments
Low debt/equity of 0.19 indicates conservative leverage, but zero reported operating cash flow and free cash flow in TTM data raises questions about cash generation quality or data availability
Current ratio of 1.62 is adequate but working capital intensity in pharma (inventory, receivables) requires continuous monitoring, particularly if revenue growth accelerates
Potential contingent liabilities from patent litigation in US generics market, where paragraph IV challenges can result in damages if unsuccessful
low - Pharmaceutical demand is relatively non-cyclical as healthcare spending on chronic and essential medicines remains stable through economic cycles. However, discretionary healthcare spending and elective procedures show modest sensitivity to consumer confidence. Export revenue has indirect cyclical exposure through destination market GDP growth affecting healthcare budgets and generic substitution rates.
Rising interest rates have modest negative impact through higher working capital financing costs (pharma companies typically carry 90-120 days of inventory and receivables) and potential valuation multiple compression for growth stocks. With debt/equity of 0.19, direct interest expense impact is limited. However, rate increases in developed markets can strengthen USD against INR, benefiting export realizations but increasing API import costs if sourced internationally.
Minimal direct credit exposure. The company's customers include government hospitals, distributors, and retail chains with generally stable payment patterns. Working capital management is more critical than credit risk, though government receivables in some states can extend beyond 120 days.
value - The stock trades at 2.3x P/S and 21.4x EV/EBITDA with 18.4% ROE, suggesting investors are focused on earnings quality and cash generation rather than high growth. The -28.9% one-year return despite 21.7% net income growth indicates market skepticism about sustainability or concerns over cash flow quality (zero reported OCF). Attracts investors seeking exposure to India's healthcare growth theme with reasonable valuations, though recent underperformance may reflect sector-wide concerns about US generics pricing or regulatory issues.
moderate-to-high - Indian mid-cap pharma stocks typically exhibit higher volatility than large-cap peers due to lower liquidity, binary outcomes from regulatory inspections, and lumpy revenue from new product launches. The -8.9% three-month decline followed by earlier gains demonstrates event-driven volatility. Sector beta to Indian equity indices is typically 0.8-1.2, with additional idiosyncratic risk from company-specific regulatory or product events.
